Goldentree Asset Management LP Purchases 4,004,889 Shares of Bausch Health Cos Inc. $BHC

Goldentree Asset Management LP raised its position in Bausch Health Cos Inc. (NYSE:BHC) by 13.2% during the 2nd quarter, Holdings Channel reports. The firm owned 34,254,889 shares of the company’s stock after acquiring an additional 4,004,889 shares during the quarter. Bausch Health Cos comprises about 22.0% of Goldentree Asset Management LP’s holdings, making the stock its biggest position. Goldentree Asset Management LP owned about 0.09% of Bausch Health Cos worth $227,848,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of BHC. Federated Hermes Inc. lifted its holdings in Bausch Health Cos by 6.4% in the 2nd quarter. Federated Hermes Inc. now owns 124,660 shares of the company’s stock valued at $830,000 after purchasing an additional 7,490 shares in the last quarter. Invesco Ltd. raised its holdings in Bausch Health Cos by 11.8% in the second quarter. Invesco Ltd. now owns 165,543 shares of the company’s stock valued at $1,103,000 after buying an additional 17,537 shares during the period. Quantbot Technologies LP lifted its holdings in shares of Bausch Health Cos by 470.3% during the 2nd quarter. Quantbot Technologies LP now owns 121,095 shares of the company’s stock valued at $806,000 after acquiring an additional 99,860 shares in the last quarter. Norges Bank purchased a new stake in shares of Bausch Health Cos in the second quarter worth about $117,000. Finally, Russell Investments Group Ltd. boosted its holdings in Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares during the period. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Price Performance

Shares of NYSE BHC opened at $6.84 on Tuesday. The company has a market capitalization of $2.54 billion, a price-to-earnings ratio of 7.05 and a beta of 0.41. Bausch Health Cos Inc. has a twelve month low of $4.25 and a twelve month high of $8.69. The company has a current ratio of 1.30, a quick ratio of 0.97 and a debt-to-equity ratio of 57.48. The firm has a 50-day moving average of $6.44 and a two-hundred day moving average of $6.43.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Finally, Barclays set a $8.00 target price on Bausch Health Cos and gave the company a “neutral” rating in a research note on Monday. Four investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.67.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.